在类风湿性关节炎中使用托法西提尼布的临床场景指南
Mahta Mortezavi1, Eduardo F Mysler2
1Pfizer Inc, 66 Hudson Boulevard, New York, NY 10001, USA.
Therapeutic advances in chronic disease
|June 26, 2023
概括
托法西替尼在不同人群和治疗阶段的类风湿性关节炎 (RA) 患者中表现出一致的疗效和安全性. 现实世界的数据和临床试验支持其用于个性化的患者护理.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 托法西提尼布是第一个被批准用于类风湿性关节炎 (RA) 的Janus激酶 (JAK) 抑制剂.
- 关于其在不同患者群体和治疗阶段的疗效和安全性,有大量的数据.
研究的目的:
- 总结托法西提尼布在类风湿性关节炎中的临床疗效和安全数据.
- 评估不同的人口统计,治疗阶段和特定亚群的数据.
主要方法:
- 临床试验,后期分析和现实研究的审查.
- 包括ORAL监测营销后安全研究的数据.
- 对患者亚群的安全性分析,包括患有心血管风险因素的老年人.
主要成果:
- 托法西替尼在不同治疗阶段和不同基线特征 (年龄,性别,种族,BMI) 的RA患者中显示出有效性.
- 对于各种各样的子群体,可获得安全数据,以告知风险效益评估.
- 该ORAL监测研究为特定患者群体提供了关键的安全见解.
结论:
- 托法西替尼的有效性和安全性数据支持其在各种RA患者群体中的使用.
- 证据使得知情的决策和个性化的治疗策略成为可能.
- 数据有助于更好地进行临床医生与患者的讨论,以便在 RA 管理中提供个性化的护理.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
Rheumatic Heart Disease III: Medical Management
22
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
22
Inflammatory Bowel Disease IV: Pharmacological Management
155
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
155
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
201
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
201
Rheumatic Heart Disease IV: Nursing Management
23
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
23
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
158
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
158


